FHI 360 works with partners in Africa, Asia, Latin America and the United States to assess the safety, acceptability and effectiveness of potential microbicides in preventing HIV and other sexually transmitted infections. Public health experts calculate that a microbicide that is even 60 percent effective against HIV could avert at least 2.5 million infections over three years. Along with the University of Pittsburgh and Magee-Womens Research Institute, FHI 360 serves as part of the Leadership and Operations Center for the Microbicides Trials Network (MTN), a worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV. FHI 360 participates in the network leadership and is primarily responsible for facilitating and managing the network’s research operations and its community engagement program. FHI 360 staff work closely with the network’s sponsors, leaders and institutional partners, investigators, staff and community representatives from clinical research sites worldwide to implement the MTN research program. This is the second seven-year funding period for FHI 360.